Magnetic Resonance Imaging in Prostate Cancer Screening
Fazekas T, Shim S, Basile G, Baboudjian M, Kói T, Przydacz M, Abufaraj M, Ploussard G, Kasivisvanathan V, Rivas J, Gandaglia G, Szarvas T, Schoots I, van den Bergh R, Leapman M, Nyirády P, Shariat S, Rajwa P. Magnetic Resonance Imaging in Prostate Cancer Screening. JAMA Oncology 2024, 10: 745-754. PMID: 38576242, PMCID: PMC10998247, DOI: 10.1001/jamaoncol.2024.0734.Peer-Reviewed Original ResearchClinically significant PCaDetection of clinically significant PcaInternational Society of Urological PathologyClinically significant PCa detectionProstate magnetic resonance imagingMagnetic resonance imagingInsignificant PCaProstate cancerProstate cancer screeningBiopsy indicationClinically significant PCa detection rateProstate-specific antigen (PSA)-based screeningMagnetic resonance imaging pathwayOdds ratioPCa detection rateSignificant PCaPI-RADS scorePSA-based screeningResonance imagingScreening pathwayTime of magnetic resonance imagingPositive predictive valuePooled odds ratioProspective cohort studyRandomized clinical trials